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Abstract
A novel cytoplasmic structure has been recently characterized by confocal and electron microscopy in H. pylori-infected
human gastric epithelium, as an accumulation of barrel-like proteasome reactive particles colocalized with polyubiqui-
tinated proteins, H. pylori toxins and the NOD1 receptor. This proteasome particle-rich cytoplasmic structure (PaCS), a sort of
focal proteasome hyperplasia, was also detected in dysplastic cells and was found to be enriched in SHP2 and ERK proteins,
known to play a role in H. pylori-mediated gastric carcinogenesis. However, no information is available on its occurrence in
neoplastic growths. In this study, surgical specimens of gastric cancer and various other human epithelial neoplasms have
been investigated for PaCSs by light, confocal and electron microscopy including correlative confocal and electron
microscopy (CCEM). PaCSs were detected in gastric cohesive, pulmonary large cell and bronchioloalveolar, thyroid papillary,
parotid gland, hepatocellular, ovarian serous papillary, uterine cervix and colon adenocarcinomas, as well as in pancreatic
serous microcystic adenoma. H. pylori bodies, their virulence factors (VacA, CagA, urease, and outer membrane proteins) and
the NOD1 bacterial proteoglycan receptor were selectively concentrated inside gastric cancer PaCSs, but not in PaCSs from
other neoplasms which did, however, retain proteasome and polyubiquitinated proteins reactivity. No evidence of actual
microbial infection was obtained in most PaCS-positive neoplasms, except for H. pylori in gastric cancer and capsulated
bacteria in a colon cancer case. Particle lysis and loss of proteasome distinctive immunoreactivities were seen in some
tumour cell PaCSs, possibly ending in sequestosomes or autophagic bodies. It is concluded that PaCSs are widely
represented in human neoplasms and that both non-infectious and infectious factors activating the ubiquitin-proteasome
system are likely to be involved in their origin. PaCS detection might help clarify the role of the ubiquitin-proteasome
system in carcinogenesis.
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Introduction
By means of electron and confocal microscopy of H. pylori-
infected gastric epithelium, we recently described a novel
cytoplasmic structure characterized by the accumulation of
particles resembling in size, shape and inner structure, the
barrel-like proteasome machinery and showing immunoreactivity
for several proteasome component proteins [1]. This proteasome
particle-rich cytoplasmic structure (PaCS) was also found to
selectively concentrate polyubiquitinated proteins, NOD1, the
intracellular H. pylori receptor [2], several bacterial products,
including VacA and CagA toxins as well as SHP2 and ERK
proteins, known to interact with CagA in gastric carcinogenesis
[1,3]. In addition to foveolar-superficial epithelium, PaCSs were
also found inside gastric dysplastic lesions and in cultured
neoplastic cell lines of gastric and non-gastric origin, especially
when incubated with H. pylori or its virulence factors [1].
These findings, together with mounting evidence supporting a
role of proteasome in cancer development and progression [4],
prompted us to investigate human epithelial neoplasms for the
presence of PaCS. Various solid neoplasms of different origin,
histology, genetic background and malignancy grade were
investigated for PaCS by ordinary or correlative light, confocal
and electron microscopy after immunostaining for proteasome
components and polyubiquitinated proteins. PaCSs were detected
in gastric, lung, thyroid, parotid, hepatocellular, colon, ovarian
and uterine cervix cancers as well as in pancreatic serous
microcystic adenoma.
Materials and Methods
Both formalin-fixed paraffin embedded surgical specimens and
formaldehyde–glutaraldehyde fixed, osmium post-fixed, Epon-
Araldite embedded specimens from the same gastric, pancreatic,
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cervix neoplasms, undergone surgery in the years 1984–1990,
were retrieved from the files of the Department of Pathology,
University of Pavia and Policlinico San Matteo Hospital. A total of
45 epithelial neoplasms were obtained. For comparison, we also
investigated archival resin (either Epon-Araldite or hydrophilic
LWR) blocks from gastric endoscopic biopsies, fixed in a
formaldehyde-glutaraldehyde solution with or without osmium
post-fixation [1]. No specimen specifically and/or exclusively
devoted to the present study was taken. The study has been
approved by the Ethics Committee of Fondazione IRCCS
Policlinico San Matteo (Pavia, Italy) as a reinvestigation of
archival material along the same line (i.e., diagnosis of pathology
in neoplastic patients) as for the original written consensus, without
the need of further consent and with communication to the
national ‘‘Garante’’ of the privacy.
Paraffin sections were stained with hematoxylin-eosin, Giemsa
or immunoperoxidase [5] using antibodies directed against
proteasome 20S, ab subunits, or the 19S, S2 subunit (both rabbit
polyclonal antibodies, Calbiochem, La Jolla, CA), polyubiquiti-
nated proteins (mouse monoclonal, FK1 clone, Enzo Life Sciences
International, Plymouth Meeting, PA), and the sequestosome
marker p62 protein (also known as SQSTM1) (rabbit polyclonal,
H-290, Santa Cruz Biotechnology, Santa Cruz, CA). Semithin
(about 0.5 mm) sections from Epon-Araldite blocks were either
stained with toluidine blue in a pH 8 borax solution for
Figure 1. H. pylori-colonized non-neoplastic human gastric epithelium (A–C) and well differentiated, gland-forming, deeply
invasive, gastric cancer (D–M). (A) Foveolar epithelium showing 20S proteasome immunofluorescence (green) of infranuclear PaCSs.
Overlapping of confocal fluorescence microscopy and toluidine blue images of a semithin resin section from an aldehyde-osmium-fixed block
(500x). (B) Juxtanuclear PaCS (asterisk) in a foveolar cell (5,000x) from an adjacent section to A.( C) High resolution (X 65,000) TEM of a boxed
PaCS area in B to show its particulate ultrastructure and 20S proteasome immunogold reactivity. (D) Toluidine blue stained semithin resin
section (500x); note pink stained PaCSs (arrowheads), many of which subluminal. (E) Correlative confocal and electron microscopy (CCEM), of a
consecutive thin section of the boxed area in D, shows 20S proteasome immunofluorescence (green spots) on a TEM background (5,000x). The
juxtaluminal PaCS (arrowhead) is enlarged in F (20,000x) whose boxed area is further enlarged in G (50,000x) to illustrate its particulate
ultrastructure with 20S proteasome immunogold reactivity. The same proteasome antibody was used on each face of the gilder finder grid used
for CCEM. Note several basally located PaCSs in E.( H) Another thin section (5,000x) from the same tumour block with several supranuclear
PaCSs, one of which (arrowhead) is enlarged in the top link inset (18,000x) to show an inner bacterial body (for comparison, another intracellular
bacterium positive for H. pylori OMPs immunogold (21,000x) is shown in the bottom right inset), while an juxtaluminal PaCS (boxed area) is
enlarged in I (25,000x) to illustrate NOD1 immunogold reactivity. N, nucleus. (L) TEM (20.000x) of another PaCS in another section from the same
block immunostained with H. pylori OMP antibodies; boxed area enlarged in M (50,000x) to better magnify the immunogold particles and barrel-
like putative proteasome particles, one of which (boxed in M) is further enlarged in the L inset (200,000x) to illustrate the characteristic
punctuate-aligned structure.
doi:10.1371/journal.pone.0021317.g001
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cence with 20S proteasome (rabbit polyclonal, PW8155, Enzo),
ubiquitinated protein (mouse monoclonal, FK2 clone, Enzo) or
p62 protein (Santa Cruz) antibodies followed by Alexa 488-
labelled anti-mouse or anti-rabbit-IgG, as appropriate. A TCS
SP2 confocal laser scanning microscope (Leica, Heidelberg,
Germany) equipped with a 63x oil-immersion objective was used.
Consecutive thin (about 0.1 mm) sections from the same resin
blocks were stained with uranyl-lead or the immunogold
procedure using antibodies against proteasome 20S, 19S or
20Sß5i (immunoproteasome; rabbit polyclonal, Calbiochem)
subunits, polyubiquitinated proteins, p62 protein, cathepsin D
(rabbit polyclonal, H-75, Santa Cruz), CagA (rabbit polyclonal,
Austral Biological, San Ramon, CA), VacA (rabbit polyclonal,
Austral Biological), urease (UreA, mouse monoclonal, Austral
Biological), H. pylori outer membrane proteins (OMPs, rabbit
polyclonal, Biomeda, Forster City, CA) and NOD1 (rabbit
polyclonal, Abnova, Taipei City, Taiwan), followed by anti-mouse
or anti-rabbit IgG labelled with 10, 15 or 20 nm gold particles
(British Biocell International, Cardiff, UK) and uranyl-lead
contrast [1]. Ultrastructural specimens were analyzed by trans-
mission electron microscopy (TEM; Jeol Jem 1200EXIII micro-
scope equipped with Olympus CCD camera Mega View III).
For correlative confocal and electron microscopy (CCEM) the
two faces of a thin resin section collected on a 200 mesh gilder
finder grid (Electron Microscopy Sciences, Hatfield, PA) were
processed separately: one face was first immunostained and
viewed by confocal microscopy, as above, then the reverse face of
the section was processed for immunogold labelling and observed
by TEM after uranyl-lead contrast. The resulting confocal and
TEM images of the same area were then overlapped using
AdobePhotoshop.
Tests to evaluate the specificity of immunogold labelling were
carried out using antibodies absorbed with excess antigen and
omitting or substituting the specific antibodies in the first layer of
the immunogold procedure. Positive and negative controls were
obtained by parallel investigation of specimens already assessed in
previous studies [1,5,6].
Figure 2. Pancreatic serous microcystic adenoma. (A, B) Formalin-fixed paraffin sections; note the clear, apparently ‘‘empty’’ cytoplasm of most
cells in A (hematoxylin-eosin, 1,000x) and the poor reactivity in B to proteasome immunofluorescence under confocal microscopy (blue: nuclei;
green: proteasome; 800x). (C, D) Semithin aldehyde-osmium fixed resin sections from the same tumour as in A and B, show abundant cytoplasmic
PaCSs metachromatically stained pink with toluidine blue (C, 1,000x) and extensively proteasome immunofluorescent under confocal microscopy (D,
green: proteasome; 500x). (E) CCEM showing proteasome immunofluorescent PaCS (5,000x); the same specimen under TEM only (F, 5,000x), boxed
area enlarged in G (50,000x) shows the PaCS particulate pattern with 20S proteasome immunogold reactivity. (H, I) TEM of another specimen of the
same tumour in H (5,000x), boxed area enlarged in I (30,000x) and further enlarged in the inset (50,000x) to show PaCS particulate ultrastructure and
19S proteasome immunogold.
doi:10.1371/journal.pone.0021317.g002
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In accordance with previous studies [1], PaCSs were identified
in aldehyde-osmium fixed, resin embedded specimens of H. pylori-
infected gastric foveolar epithelium as well-defined cytoplasmic
areas metachromatically stained pink by toluidine blue and
selectively immunofluorescent with antibodies directed against H.
pylori proteins, proteasome (Figure 1A) or polyubiquitinated
proteins. Under electron microscopy, PaCSs showed character-
istic barrel-like particles, about 13 nm thick and 15 to 40 nm
long, with an inner punctate substructure, and selective
immunogold reactivity for proteasome (Figure 1B and C),
polyubiquitinated proteins, NOD1, VacA, CagA, urease and
OMPs, but not for p62 protein or the lysosomal marker cathepsin
D. Using the same procedures, PaCSs were also identified in two
of five gastric gland-forming (cohesive, so-called ‘intestinal’)
cancers, with all the structural and cytochemical patterns shown
in non-tumour gastric epithelium (Figure 1D–M). In addition,
cytoplasmic areas reproducing PaCS ultrastructure and protea-
some as well as ubiquitinated proteins reactivity, though without
H. pylori products and NOD1, were detected in pancreatic serous
microcystic adenoma (Figure 2), basal cell parotid gland cancer
(Figure 3), ovarian serous papillary, uterine cervical and thyroid
papillary carcinoma (Figure 4), pulmonary large cell, bronchio-
loalveolar and hepatocellular carcinoma (Figure 5A–E), appar-
ently in the absence of actual infection. On the other hand, both
PaCSs and capsulated (Gram-positive) bacteria were detected
inside one case of colon carcinoma (Figure 5F–H). PaCSs were
not observed in gastric diffuse, ovarian mucinous and breast
ductal cancers. Nuclear areas filled with proteasome-like
particles, ultrastructurally and cytochemically indistinguishable
from those of PaCS, were also found in one case of parotid cancer
(Figure 3F and G).
Compared with those of non-neoplastic cells, tumour PaCSs
were more often multifocal, less polarized to the infranuclear
cytoplasm, less sharply demarcated from the surrounding
cytoplasm and less closely related to ribosome-rich RER.
However, large quantitative differences were found from neoplasm
to neoplasm, ranging from extensive, fairly uniform areas
expanding to occupy most of the cytoplasm in the vast majority
of tumour cells, as in pancreatic microcystic adenoma (Figure 2C
and D), or in a minority of cells, as in gastric, salivary gland or
thyroid cancer, to individual, minute foci inside a few tumour cells
as in most other tumours.
Figure 3. Parotid gland cancer. (A) CCEM shows proteasome immunofluorescence (green) distributed inside cytoplasmic PaCSs while sparing the
nucleus (A, 3,000x). The boxed area is enlarged in B (50,000x) to magnify parallel 20S immunogold reactivity despite loss of density of barrel-like
particles. Note in A mitochondria and clear unreactive areas merging with PaCS areas. In C (3,000x) a ballooning tumour cell with remnant of a
central picnotic nucleus (arrow) is almost entirely formed by a degenerating PaCS only partly reactive to proteasome fluorescence. The boxed area,
taken in C at the transition border between its highly and poorly fluorescent parts, shows in D (50,000x) the disappearance of particles and 20S
proteasome immunogold below the border, in parallel with immunofluorescence. Another boxed area taken from the top of the heavily fluorescent
part in C, shows well-preserved particles and proteasome immunogold in E (50,000x). (F and G) TEM (5,000x) showing two neoplastic cells, one with
well-preserved normal nucleus (left), the other (right) with intranuclear accumulation of PaCS-like particles and proteasome immunogold, part of
which is boxed in F and enlarged in G (50,000x). Note in F abundant mitochondria. n, nucleolus. (H) Bulging neoplastic cell with a small nucleus
surrounded by a rim of dense cytoplasm and immersed in a lake of PaCS-type partly proteasome-reactive, particulate material (4,000x); the boxed
area is enlarged in I (20,000x) with islets of residual cytoplasm, one of which is further enlarged in L (75,000x) to show a qualitative autophagic vesicle
with double membrane enclosing a collection of well-preserved immunoproteasome-reactive PaCS-type particles. Note in H and I (arrowheads) three
other double membrane delimited bodies enclosing PaCS-type particles.
doi:10.1371/journal.pone.0021317.g003
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neoplastic and non-neoplastic cell PaCSs retained direct continuity
with the surrounding cytoplasm, without interposition of mem-
branes, and lacked p62 protein or cathepsin D immunoreactivity.
Of special interest was the p62 protein reactivity of hyaline bodies
in hepatocellular carcinoma, in contrast with the unreactivity of
most PaCSs observed in the same sections (Figure 5D and E).
However, in parotid gland cancer, small, double membrane
delimited bodies filled with well-preserved proteasome particles
were seen, occasionally, inside PaCSs undergoing partial dissolu-
tion (Figure 3H–L). Indeed, TEM detected focal to extensive loss
of particles inside PaCSs of some neoplasms, leaving a loose
amorphous to filamentous or floccular material often with
reduction or even disappearance of proteasome immunoreactivity
(Figures 3C–E, 4G–I, and 5H). This lytic process is likely to be
involved in the genesis of some amorphous structures or clear
areas void of proteasome particles (Figure 3C and D), or of
membrane-delimited vacuoles with variable, often irregular
content more suggestive of autophagic vacuoles, sometimes with
residual particles and proteasome immunoreactivity (Figure 5F–
H). No apparent difference of mitochondria ultrastructure was
seen in PaCS-positive compared to PaCS-negative cells (not
shown).
Proteasome particles were not preserved in gastric biopsies
fixed with aldehyde solutions in the absence of osmium
post-fixation, embedded in Epon-Araldite or hydrophilic LWR
resin, and viewed by TEM, although proteasome protein
reactivity was retained, at least in part, thus allowing PaCS
recognition. This highlights the crucial fixation conditions
required for particle structure preservation and its tendency to
dissolve, releasing component proteins, in suboptimal condi-
tions. This may help explain why we failed to detect PaCSs
in ordinary formalin-fixed paraffin sections, stained with
toluidine blue or proteasome antibodies, even in tumours like
pancreatic serous microcystic adenoma where PACSs were
extensively seen in aldehyde-osmium resin sections (Figure 2A–
D). Thus, poor PaCS fixation by routine acqueous aldehyde
solutions may contribute to the extensively ‘‘cleared’’ cytoplasm
of serous microcystic adenoma, usually attributed to dissolu-
tion of their glycogen content in aqueous fixatives. Both hyaline
and Mallory bodies were heavily immunoreactive for p62
protein in formalin-fixed paraffin sections of hepatocellular
carcinoma (Figure 5D inset), whereas under the same tech-
nical conditions no p62 reactivity was detected in the large
clear PaCS-enriched cytoplasmic areas of serous microcystic
adenoma.
Figure 4. Ovarian serous papillary, cervical endometrioid, and thyroid papillary carcinomas. Juxtanuclear PaCSs in ovarian serous
papillary (A, 10,000x), cervical endometrioid (D, 10,000x), and thyroid papillary carcinoma (G, 10,000x), enlarged in B, E, and H (all 25,000x) and even
further in C, F, and I (all, 50,000x), respectively, to show their particulate ultrastructure (partially lost in I and, focally, in F) and 20S proteasome
immunogold reactivity.
doi:10.1371/journal.pone.0021317.g004
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This investigation documents the presence of PaCSs, the
barrel-like particles and proteasome-rich cytoplasmic structures
we recently identified in H. pylori-infected gastric epithelium [1],
in gastric cancer cells. Colocalization inside cancer cell PaCS of
H. pylori virulence factors like VacA, CagA, urease or outer
membrane proteins, the H. pylori receptor NOD1, polyubiqui-
tinated proteins, and, occasionally, of H. pylori itself, nicely
reproduce the ultrastructural and cytochemical patterns of such
structures as already detailed in non-neoplastic gastric epitheli-
um and in epithelial cell lines incubated with H. pylori culture
filtrate. The present findings, together with previous detection of
H. pylori inside dysplastic intramucosal lesions and invasive
cancer [6], support the hypothesis that H. pylori has a direct role
in the genesis of PaCS and, possibly, in gastric carcinogenesis
[3].
Nevertheless, PaCSs with proteasome-rich particles and poly-
ubiquitinated proteins, albeit in the absence of H. pylori products
and NOD1, were also observed in various epithelial neoplasms
arising in the digestive (pancreas, parotid, colon, and liver),
respiratory (lung) and female genital tract (ovary, cervix) or even in
endocrine glands (thyroid). In addition, proteasome particle-rich
structures have also been detected in the nucleus, a known site of
proteasome distribution [7], of a parotid gland cancer. The
negative findings so far obtained in cases of gastric diffuse, ovarian
mucinous and breast ductal carcinomas warrant more extensive
investigation. However, the present evidence suggests preferential
involvement of neoplasms with serous (proteic) secretory potential
and variable degrees of glandular differentiation or histologic
grade, from benign (pancreatic serous microcystic adenoma) to
highly malignant (pulmonary large cell carcinoma).
In essence, PaCSs may result from focal accumulation inside
RER areas of barrel-like particles, likely to be identified with the
Figure 5. Lung large cell carcinoma, hepatocarcinoma and colon adenocarcinoma. (A–C) Juxtanuclear PaCS in a lung large cell carcinoma
(A, 10,000x), boxed area enlarged in B (50,000x) whose boxed area is enlarged in C (75,000x) to show its particulate structure and proteasome
immunogold reactivity. (D and E) Hepatocellular carcinoma showing both hyaline bodies (hb), reactive for p62 protein in D (30,000x) and unreactive
for 19S proteasome in E (25,000x), and PaCS (asterisks) unreactive for p62 and reactive for 19S proteasome. r, ribosomes. Inset to D (450x): hyaline
and Mallory bodies react for p62 protein immunoperoxidase in formalin-fixed paraffin sections. (F–H) Colon adenocarcinoma (F, 10,000x) with partly
intracellular and partly interstitial bacteria, a cytoplasmic vacuole (v) and a PaCS (boxed) bordering the cell plasma membrane, enlarged in G
(40,000x) and H (75,000x). Note partial lysis of proteasome particles, though retaining 19S proteasome reactivity, development of irregular dense
bodies and an encircling peripheral membrane, suggesting transition from a PaCS to an autophagic vacuole, also enclosing ribosome-like particles (r)
and a bacterium (top right in G and H) with capsulated wall typical of Gram-positive organisms.
doi:10.1371/journal.pone.0021317.g005
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tive proteins synthesized at ribosome level (or redistributed there)
under cell stimulation, a sort of focal proteasome hyperplasia [1].
As to the nature of the stimulus for this cellular change, previously
observed PaCS development in HeLa cells incubated in vitro with
H. pylori culture filtrates and PaCS localization of H. pylori itself and
its virulence factors in infected gastric epithelium [1], here
confirmed and extended to gastric cancer, suggests that H. pylori
infection is involved in eliciting proteasomal stimulation. This
conclusion would fit in with the known role of the ubiquitin-
proteasome system (UPS), with special reference to immunopro-
teasome [8], in mounting a class I MHC-dependent cellular
immune response to microbial infection and with our detection of
immunoproteasome components inside the PaCS. However, no
sign of actual microbial infection has so far been detected in the
other PaCS-positive neoplasms investigated, with the only
exception of a colon cancer. Thus, besides infection, a more
general mechanism eliciting UPS-based cellular responses is likely
to be involved. In this context, a link with inflammation and
inflammatory cytokines or LPS-induced oxidative stress resulting
in neosynthesis of oxidant-damaged misfolded proteins undergoing
rapid polyubiquitination seems attractive [9]. It also seems of
interest that H. pylori and its CagA toxin can induce reactive
oxygen species (ROS) in gastric epithelial cells, both directly and
secondary to associated gastritis [10], a process which may have a
role in carcinogenesis in addition to PaCS formation.
PaCSs clearly differ ultrastructurally and cytochemically from a
number of cytoplasmic inclusion bodies, including hepatocellular
hyaline or Mallory bodies, inclusions of various neurodegenerative
diseases and other sequestosomes or aggresomes [11–13], which
may share with PaCS a reactivity for polyubiquitinated proteins
while usually lacking substantial proteasome reactivity and
showing, in addition, p62 protein. Per se, most PaCSs also differ
sharply from ubiquitinated protein-reactive, but generally protea-
some-negative, autophagic structures, either autophagosomes or
autolysosomes, as they lack distinctive features like isolation
membranes, p62 protein and inner remnants of cytoplasmic
organules or irregular, lysosome-like dense bodies [14]. However,
ultrastructural patterns suggesting transition, through progressive
loss of particles and proteasome immunoreactivity, from PaCS to
amorphous-filamentous structures of the type identified by Bjorkoy
et al. [15] as p62-positive sequestosomes destined to autophagy,
have been observed in some neoplastic cells, either in vivo from
tumour samples (this study) or in cultured cell lines [1]. In
addition, a few autophagosome-like, double membrane-enveloped
bodies filled with proteasome particles were found in parotid gland
cancer, inside degenerating PaCSs undergoing dissolution. Thus,
although PaCSs and their nuclear equivalents are, per se, clearly
different from known inclusion bodies and apparently unrelated to
autophagy, when undergoing particle dissolution and proteasome
loss (a frequent finding in some neoplasms) they might well be
involved in sequestosome formation and autophagy-related
degradative processes.
To our knowledge, no specific molecular change is shared by
the full spectrum of PaCS-positive cells and neoplasms we have
observed, with the possible exception of MAPK-ERK pathway
activation [16,17], either through EGFR overexpression/activa-
tion, as in H. pylori-infected gastric cells [18] and in pancreatic
serous cystic adenoma [19], or through constitutive ERK
activation, often secondary to EGFR, RAS or BRAF mutation,
as found in hepatocellular, lung, thyroid papillary, ovarian and
colorectal cancers [20–24]. Interestingly, ERK protein immuno-
reactivity has been detected inside PaCS of H. pylori-infected
gastric epithelium [1].
In conclusion, PaCSs may develop in neoplastic and non-
neoplastic cells which have undergone functional overstimulation
of the ubiquitin-proteasome system due to various stimuli, as for
instance microbial infections, oxidative stress or excessive poly-
ubiquitinated protein production/accumulation, to which a
contribution of proteasome loss or malfunction preventing rapid
degradation of ubiquitinated proteins [9,25] is possibly to be
added. While clarification of PaCS role in cellular homeostasis
requires further investigation, its frequent occurrence in neoplasms
deserves attention, especially in the light of present therapeutic
approaches targeting proteasome [4].
Author Contributions
Conceived and designed the experiments: PS VR ES. Performed the
experiments: VN PS AV RM. Analyzed the data: VN PS VR ES. Wrote
the paper: VR ES.
References
1. Necchi V, Sommi P, Ricci V, Solcia E (2010) In vivo accumulation of Helicobacter
pylori products, NOD1, uniquitinated proteins and proteasome in a novel
cytoplasmic structure. PLoS One 5: e9716.
2. Viala J, Chaput C, IG, Cardona A, Girardin SE, et al. (2004) Nod1 responds to
peptidoglycan delivered by the Helicobacter pylori cag pathogenicity island. Nat
Immunol 5: 1166–1174.
3. Hatakeyama M (2004) Oncogenic mechanisms of the Helicobacter pylori CagA
protein. Nat Rev Cancer 4: 688–694.
4. Hoeller D, Dikic I (2009) Targeting the ubiquitin system in cancer therapy.
Nature 458: 438–444.
5. Fiocca R, Necchi V, Sommi P, Ricci V, Telford J, et al. (1999) Release of
Helicobacter pylori vacuolating cytotoxin by both a specific secretion pathway and
budding of outer membrane vesicles. Uptake of released toxin and vesicles by
gastric epithelium. J Pathol 188: 220–226.
6. Necchi V, Candusso ME, Tava F, Luinetti O, Ventura U, et al. (2007)
Intracellulare, intercellular, and stromal invasion of gastric mucosa, preneopals-
tic lesions, and cancer by Helicobacter pylori. Gastroenterology 132: 1009–1023.
7. Rivett J, Palmer A, Knecht E (1992) Electron microscopy localization of the
multicatalytic proteinase complex in rat liver and in cultured cells. J Histochem
Citochem 40: 1165–1172.
8. Fehling HJ, Swatt W, Laplace C, Kuhn R, Rajewsky K, et al. (1994) MHC class
I expression in mice lacking proteasome subunit LMP-7. Science 265:
1234–1237.
9. Seifert U, Bialy LP, Ebstein F, Bech-Otschir D, Voigt A, et al. (2010)
Immunoproteasomes preserve protein homeostasis upon interferon-induced
oxidative stress. Cell 142: 613–624.
10. Handa O, Naito Y, Yoshikawa T (2007) CagA protein of Helicobacter pylori:a
hijacker of gastric epithelial cell signaling. Biochem Pharmacol 73: 1697–1702.
11. Kopito RR (2000) Aggresomes, inclusion bodies and protein aggregation.
Trends Cell Biol 10: 524–530.
12. Denk H, Stumptner C, Fuchsbichler A, Mu ¨ller T, Farr GH, et al. (2006) Are the
Mallory bodies and intracellular hyaline bodies in neoplastic and non-neoplastic
hepatocytes related? J Pathol 208: 653–661.
13. Szeto J, Kaniuk NA, Canadien V, Nisman R, Mizushima N, et al. (2006) ALIS
are stress-induced protein storage compartments for substrates of the proteasome
and autophagy. Autophagy 2-3: 189–199.
14. Glick D, Barth S, Macleod KF (2010) Autophagy: cellular and molecular
mechanisms. J Pathol 221: 3–12.
15. Bjorkoy G, Lamark T, Brech A, Outzen H, Perander M, et al. (2005) p62/
SQSTM1 forms protein aggregates degraded by autophagy and has a protective
effect on huntingtin-induced cell death. J Cell Biol 171: 603–614.
16. Meyer-ter-Vehn T, Covacci A, Kist M, Pahl HL (2000) Helicobacter pylori
activates mitogen-activated protein kinase cascades and induces expression of
the proto-oncogenes c-fos and c-jun. J Biol Chem 275: 16064–16072.
17. Roberts PJ, Der CJ (2007) Targeting of Raf-MEK-ERK mitogen-activated
protein kinase cascade for the treatment of cancer. Oncogene 26: 3291–3310.
18. Keates S, Keates AC, Katchar K, Peek RM, Kelly CP (2007) Helicobacter pylori
induces up-regulation of the epidermal growth factor receptor in AGS gastric
epithelial cells. J Infect Dis 196: 95–103.
19. Kuboki Y, Shiratori K, Hatori T, Fujita I, Kimijima A, et al. (2010) Association
of epidermal growth factor receptor and mitogen-activated protein kinase with
cystic neoplasms of the pancreas. Mod Pathol 23: 1127–1135.
PaCSs in Epithelial Neoplasms
PLoS ONE | www.plosone.org 7 June 2011 | Volume 6 | Issue 6 | e2131720. Ito Y, Sasaki Y, Horimoto M, Wada S, Tanaka Y, et al. (1998) Activation of
mitogen-activated protein kinases/extracellular signal-regulated kinases in
human hepatocellular carcinoma. Hepatology 27: 951–958.
21. Brose MS, Volpe P, Feldman M, Kumar M, Rishi I, et al. (2002) BRAF and
RAS mutations in human lung cancers and melanoma. Cancer Res 62:
6997–7000.
22. Kimura ET, Nikiforova MN, Zhu Z, Knauf JA, Nikiforov YE, et al. (2003) High
prevalence of BRAF mutations in thyroid cancer: genetic evidence for
constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in
papillary thyroid carcinoma. Cancer Res 63: 1454–1457.
23. Sieben N, Macropoulos P, Roemen G, Kolkman-Uljee SM, Fleuren GJ, et al.
(2004) In ovarian neoplasms, BRAF, but not KRAS, mutations are restricted to
low-grade serous tumours. J Pathol 202: 336–340.
24. Schmitz KJ, Wohlschlaeger J, Alakus H, Bohr J, Stauter MA, et al. (2007)
Activation of xtracellular regulated kinases (ERK1/2) but not AKT predicts
poor prognosis in colorectal carcinoma and is associated with k-ras mutations.
Virchows Arch 450: 151–159.
25. Bennett EJ, Bence NF, Jayakumar R, Kopito RR (2005) Global impairment of
the ubiquitin-proteasome system by nuclear or cytoplasmic protein aggregates
precedes inclusion body formation. Mol Cell 17: 351–365.
PaCSs in Epithelial Neoplasms
PLoS ONE | www.plosone.org 8 June 2011 | Volume 6 | Issue 6 | e21317